Table 2.
Infectious risk comparing JAK inhibitor and TNF inhibitor users
|
JAK inhibitor n = 2 963 |
TNF inhibitor (Ref) n = 5 169 |
HR (95% CI) | |||||
|---|---|---|---|---|---|---|---|
| Events | PY | aIR (95% CI) | Events | PY | aIR (95% CI) | ||
| As-treated analysis | |||||||
| Herpes zoster | 361 | 3128 | 11.54 (10.47–12.72) | 221 | 4528 | 4.88 (4.29–5.55) | 2.37 (2.00–2.80) |
| Serious herpes zoster | 62 | 3435 | 1.81 (1.41–2.31) | 11 | 4682 | 0.24 (0.13–0.42) | 7.43 (3.91–14.11) |
| Serious bacterial infection | 48 | 3445 | 1.39 (1.05–1.85) | 61 | 4629 | 1.32 (1.03–1.69) | 1.04 (0.71–1.52) |
| Opportunistic infection | 4 | 3489 | 0.11 (0.04–0.31) | 23 | 4686 | 0.49 (0.33–0.74) | 0.25 (0.09–0.73) |
| 365-day ITT | |||||||
| Herpes zoster | 242 | 2173 | 11.14 (9.89–12.54) | 211 | 4072 | 5.18 (4.54–5.91) | 2.15 (1.79–2.59) |
| Serious herpes zoster | 37 | 2263 | 1.64 (1.19–2.25) | 12 | 4156 | 0.29 (0.16–0.51) | 5.77 (3.00–11.12) |
| Serious bacterial infection | 36 | 2260 | 1.59 (1.15–2.20) | 61 | 4133 | 1.48 (1.15–1.89) | 1.08 (0.72–1.63) |
| Opportunistic infection | 3 | 2274 | 0.13 (0.04–0.41) | 16 | 4155 | 0.39 (0.24–0.63) | 0.35 (0.10–1.20) |
CI Confidence interval, HR Hazard ratio, IR Incidence rate, ITT Intention-to-treat, PY Person-years
aPer 100 person-years